InMed Pharmaceuticals: Dated Alerts Withdrawn
ByAinvest
Monday, Dec 15, 2025 10:09 am ET1min read
INM--
InMed Pharmaceuticals is a pharmaceutical company developing a pipeline of small molecule drug candidates targeting CB1/CB2 receptors. Its pipeline includes programs for Alzheimer's disease, dry age-related macular degeneration, and Epidermolysis Bullosa. INM-901 is a potential treatment for Alzheimer's, INM-089 is a cannabinoid analog for age-related macular degeneration, and INM-755 is a cannabinol topical cream for Epidermolysis Bullosa.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet